19 October 2026 · Draft for founder and qualified legal review. Not legal advice or approved launch terms. Implementation does not authorise public deployment.
Confirm company particulars against an official source; approve operation-specific lawful bases and retention; establish rights handling, manual deletion, provider agreements and transfer safeguards; verify deployed storage, hosting logs, security and payment-provider behaviour. Privacy contact: hello@aqorio.com. Optional app tracking is disabled and fonts are served locally.
External AI/audio, new UAE enquiries and shared free-text writes are paused during review. Existing authentication is preserved. Server pauses are not a substitute for reviewing database access policies before release.
No patient or clinical data may be entered. A future practice processor service needs an approved processing agreement, verified regional arrangements, tenant and role isolation tests, secure retention/deletion, restoration evidence and clinical governance. A demo role, country choice, test payment or reviewer approval does not activate clinical access.
Only approved UK/US monthly prices are configured for test checkout. Annual equivalents are not annual subscription charges. UAE AED prices, commercial terms, any trial and production activation remain unapproved and inactive. No new refund or trial commitment is made here.
View Test Plan PricingHosting/database regions, backups, international transfers, provider retention, contracts and ICO fee assessment remain open. No certification, ICO registration, residency guarantee or legal approval is claimed. The internal launch-readiness record separates implemented controls from missing evidence and founder decisions.